Smoking Cessation Aids - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the smoking cessation aids market size is estimated at USD 37.73 billion in 2026, and is expected to reach USD 64.05 billion by 2031, at a CAGR of 11.17% during the forecast period (2026-2031).

This report is Segmented by Product Type (Nicotine Replacement Therapy (NRT) [Patches, Gums and More], Prescription Pharmacotherapies [Varenicline and More] and More), Distribution Channel (Retail Pharmacies and Drug Stores, Hospital Pharmacies, and More), End User (Individual Self-Use, and More), and Geography (North America, and More). Market Forecasts are Provided in Value (USD).

Global Smoking Cessation Aids Market Trends and Insights

Rising Quit Attempts Post-COVID-19 Pandemic

Hospital admission data showed smokers experienced a 1.8-fold higher risk of severe COVID-19, driving a 23% spike in quitline calls during 2024 compared with pre-pandemic levels. Persisting respiratory complications make continued use physiologically difficult for many former patients, so cessation is now seen as essential care. The United Kingdom's Swap to Stop campaign distributed free starter vape kits to 350,000 adults by mid-2025 and doubled six-month quit rates compared with unaided attempts. Although the surge is expected to plateau by 2028, sustained public-health messaging under the WHO Framework Convention on Tobacco Control keeps the pressure high. These combined forces provide the smoking cessation aids market with a large influx of motivated quitters.

Government Tobacco-Control Taxes and Smoke-Free Laws

Australia lifted pack prices to AUD 50 (USD 33) in 2024 and cut adult smoking prevalence to 8.3%. Similar tax escalators in Canada and India narrowed the price gap between cigarettes and OTC patches that cost CAD 35 per two-week supply. Brazil's 2025 extension of smoke-free zones reduces social triggers and normalizes abstinence. These measures compress combustibles' affordability, inducing more quit attempts and buoying the smoking cessation aids market.

Adverse-Event Recalls (Varenicline Nitrosamines)

Pfizer's recall removed varenicline for three years, forcing physicians to default to less effective options until reformulated tablets returned in 2024. By late 2024, prescriptions regained only 62% of prior volume, as clinicians waited for long-term safety data. New generics from Indian manufacturers entered Europe at lower prices yet face batch-testing rules that raise costs. The episode dented patient trust, with 34% now favoring unregulated alternatives.

Other drivers and restraints analyzed in the detailed report include:

1. OTC Switch and Wider Reimbursement of NRT Products
2. Digital Health Integration (Apps, Quitlines)
3. Stringent E-Cigarette Flavor Bans

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Electronic nicotine delivery systems accounted for 47.25% of smoking cessation aids market revenue in 2025. Heated tobacco devices and nicotine pouches grew fastest inside the segment, fueled by IQOS ILUMA and Zyn distribution. Nicotine-replacement therapy (NRT) held 28%, with patches making up 42% of NRT receipts thanks to once-daily dosing and established reimbursement tracks. Prescription therapies contributed 18% but still lag due to the recent varenicline recall and uneven cytisine approvals.

Behavioral support and services will outpace all other lines with a 14.76% CAGR through 2031 as payers bundle counseling with medicines. Digital apps and quitlines, while small today, are mandatory components for many insurance plans. That shift enlarges total addressable demand and broadens competitive entry points for software-only players. Overall, the product mix highlights an incremental transition from pure pharmacotherapy toward holistic packages that blend devices, drugs, and coaching, a structure that broadens smoking cessation aids market share opportunities for newcomers.

Complete Report Scope:

• By Product Type
  • Nicotine Replacement Therapy (NRT)
    • Patches
    • Gums
    • Lozenges
    • Sprays & Inhalers
    • Other Oral & Transdermal
  • Prescription Pharmacotherapies
    • Varenicline
    • Bupropion
    • Cytisine
    • Combination Therapies
  • Electronic Nicotine Delivery Systems (ENDS)
    • E-cigarettes / Vaping Devices
    • Heated Tobacco Products
    • Nicotine Pouches (Tobacco-Free Oral)
  • Behavioral Support & Services
    • Digital / Mobile Apps
    • Telephone Quitlines
    • In-person Counseling Programs
• By Distribution Channel
  • Retail Pharmacies & Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies & E-commerce
  • Specialist Smoke/Vape Shops
• By End User
  • Individual / Consumer Self-Use
  • Healthcare-Professional-Supervised (Clinics & De-addiction Centers)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 34.83% of 2025 revenue. The United States alone contributed USD 12.4 billion, buoyed by Medicare's expanded counseling coverage and private payers' willingness to fund dual-form NRT. Flavor bans in several states created a near-term drag on ENDS but simultaneously drove patch and gum sales. Canada's indexed excise tax further narrowed price gaps, sustaining demand for regulated substitutes.

Asia-Pacific posted the fastest growth, projected at a 12.79% CAGR. China's ban on flavored e-cigarettes in 2024 redirected consumers to hospital pharmacy channels where patches and prescriptions dominate. India's 2024 legal age hike and expanded pictorial warnings increase quit attempts, especially among urban smokers who already face higher cigarette prices. Employers in both countries now subsidize cessation programs, broadening access for middle-income groups. Low-cost cytisine also resonates in budget-constrained populations.

Europe supplied nearly 1/4th of 2025 turnover, led by the UK, Germany, and France. The UK's Swap to Stop added 360,000 users and showed policy openness to harm-reduction pathways. Eastern European markets embraced cytisine due to attractive pricing, while Western payers still prioritize varenicline and dual-form NRT. The Middle East & Africa is supported by Gulf state investments in national quitlines, while South America is anchored by Brazil's promise of universal pharmacotherapy coverage despite distribution gaps in remote regions. Collectively, these dynamics underscore varied regional drivers yet all funnel additional revenue into the smoking cessation aids market.

1. 22nd Century Group Inc.
2. Alkalon A/S
3. Axsome Therapeutics
4. British American Tobacco plc
5. Cipla
6. Ditch Labs Inc.
7. Dr. Reddy's Laboratories Ltd.
8. Enorama Pharma AB
9. Glenmark Pharmaceuticals
10. Haleon plc
11. Imperial Brands plc
12. Japan Tobacco International
13. Johnson & Johnson (McNeil)
14. Lucy Goods Inc.
15. Perrigo Company
16. Pfizer
17. Philip Morris International Inc.
18. Rubicon Research Pvt. Ltd.
19. Rusan Pharma Ltd.
20. Sparsha Pharma International Pvt. Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support